AVDL$21.48
$21.4512
Chart
Performance
Key Stats
AI AVDL Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyAvadel Pharmaceuticals shows positive momentum and strong future prospects driven by its product pipeline, despite current unprofitability and some technical overbought signals.
Thematic
Avadel operates in the attractive narcolepsy treatment market with LUMRYZ, a product with significant growth potential.
Fundamental
Avadel is currently unprofitable with negative EPS, but revenue is growing. The balance sheet shows manageable debt and positive cash flow from operations.
Technical
The stock has shown strong upward momentum, trading above key moving averages, but some oscillators indicate it may be approaching overbought territory.
| Factor | Score |
|---|---|
| Narcolepsy Treatment Market Growth | 90 |
| Biopharmaceutical Innovation | 85 |
| Regulatory Landscape | 65 |
| Competitive Environment | 70 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 20 |
| Growth | 70 |
| Balance Sheet Health | 95 |
| Cash Flow | 40 |
| Factor | Score |
|---|---|
| Trend Analysis | 80 |
| Momentum | 60 |
| Volume Confirmation | 65 |
| Support & Resistance | 75 |
AI Investing Checklist
Powered by LiveAIBullish Points (9)
Strong Short-Term Performance
The stock has shown strong performance over various short-term periods, with 5-day performance at 9.06%, 1-month at 19.28%, and 6-month at 38.61%.
Sufficient Cash Reserves
The company has a healthy cash position, with cash equivalents of $51.37 million as of 2024Q4, providing liquidity for operations and potential investments.
Bearish Points (11)
Negative Earnings Per Share (TTM)
The company has a negative EPS TTM of -0.26, indicating it is currently not profitable on a per-share basis.
Net Losses Reported
The company has consistently reported net losses in recent periods, with a net income of -$48.83 million in 2024Q4, indicating ongoing profitability challenges.
Calendar
August 2025
7
Next Earnings Date
H: $0.05
A: $0.03
L: $0.02
H: 63.80M
A: 61.46M
L: 59.00M
Profile
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Seasonals
Price Target
16.57 USD
The 39 analysts offering 1 year price forecasts for AVDL have a max estimate of 22.00 and a min estimate of 13.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Primary competitor in narcolepsy with Xyrem and Xywav, directly targeting the same sleep-wake disorder market as Avadel's LUMRYZ.
Weight: 95
Direct competitor in narcolepsy with Wakix, offering an alternative mechanism of action for the same condition Avadel addresses.
Weight: 92
Competitor in narcolepsy and excessive daytime sleepiness (EDS) with Sunosi, addressing related sleep-wake disorders.
Weight: 88
Specializes in CNS disorders, including sleep disorders (Hetlioz for Non-24-hour sleep-wake disorder), aligning with Avadel's therapeutic area.